JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schmitz-Peiffer, C.
Right arrow Articles by Biden, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmitz-Peiffer, C.
Right arrow Articles by Biden, T. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 34, 24202-24210, August 20, 1999


Ceramide Generation Is Sufficient to Account for the Inhibition of the Insulin-stimulated PKB Pathway in C2C12 Skeletal Muscle Cells Pretreated with Palmitate*

Carsten Schmitz-PeifferDagger , Denby L. Craig, and Trevor J. Biden

From The Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, New South Wales, Australia 2010

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We have employed C2C12 myotubes to investigate lipid inhibition of insulin-stimulated signal transduction and glucose metabolism. Cells were preincubated for 18 h in the absence or presence of free fatty acids (FFAs) and stimulated with insulin, and the effects on glycogen synthesis and signaling intermediates were determined. While the unsaturated FFAs oleate and linoleate inhibited both basal and insulin-stimulated glycogen synthesis, the saturated FFA palmitate reduced only insulin-stimulated glycogen synthesis, and was found to inhibit insulin-stimulated phosphorylation of glycogen synthase kinase-3 and protein kinase B (PKB). However, no effect of palmitate was observed on tyrosine phosphorylation, p85 association, or phosphatidylinositol 3-kinase activity in IRS-1 immunoprecipitates. In contrast, palmitate promoted phosphorylation of mitogen-activated protein MAP) kinases. Ceramide, a derivative of palmitate, has recently been associated with similar inhibition of PKB, and here, ceramide levels were found to be elevated 2-fold in palmitate-treated C2C12 cells. Incubation of C2C12 cells with ceramide closely reproduced the effects of palmitate, leading to inhibition of glycogen synthesis and PKB and to stimulation of MAP kinase. We conclude that palmitate-induced insulin resistance occurs by a mechanism distinct from that of unsaturated FFAs, and involves elevation of ceramide by de novo synthesis, leading to PKB inhibition without affecting IRS-1 function.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Skeletal muscle is the most important target of insulin action in terms of post-prandial glucose disposal, and skeletal muscle insulin resistance is a major characteristic of non-insulin-dependent diabetes mellitus (1). The mechanisms by which muscle becomes less sensitive to the hormone are still unclear; however, there is a strong correlation between insulin resistance and increased lipid availability in the tissue (2). Evidence for this has been derived from studies involving obese humans (3, 4) and animals (5), animals fed high-fat diets (6, 7), and the exposure of muscle cells to increased lipid levels (8, 9).

The signaling pathways involved in the metabolic actions of insulin are becoming well characterized. The stimulation of glycogen synthesis from glucose by insulin (reviewed in Ref. 10) involves activation of PI3-kinase1 through association of this enzyme with IRS molecules that have been tyrosine phosphorylated by the insulin receptor (11). IRS-1 may be the predominant adaptor molecule responsible for metabolic signals, especially in muscle (12), although IRS-2 and further adaptor molecules also play roles (13). PI3-kinase catalyzes the production of PtdIns(3,4,5)P3 which leads to the activation of PKB (also known as Akt or RAC kinase), through the sequential phosphorylation on Thr-308 and Ser-473 by PDK1 and PDK2, respectively (14). PKB in turn phosphorylates and inhibits GSK-3alpha at Ser-21 (15). GSK-3alpha is thought to be the most important kinase regulating glycogen synthase activity, through inhibition by phosphorylation (16). Thus the insulin-stimulated increase in glycogen synthesis involves net dephosphorylation of glycogen synthase, largely by decreased activity of GSK-3alpha , although increased phosphatase activity may also play a role (17). The relative importance of insulin-stimulated glycogen synthesis versus glucose transport, mediated by increased plasma membrane GLUT4 glucose transporter levels, in determining the rate of glucose disposal by muscle remains controversial although it appears that glycogen synthesis is rate-limiting at higher levels of insulin (10, 18). Defects in muscle glycogen synthesis have a dominant role in the insulin resistance that occurs in non-insulin-dependent diabetes mellitus (19).

Insulin also activates MAP kinase pathways, which may be more involved in its mitogenic rather than its metabolic effects. IRS-1 and a further adaptor molecule Shc appear to be responsible for the activation of p21ras, via Grb2 and mSOS, and hence the kinases downstream leading to ERK MAP kinase activation (13). Evidence is emerging that insulin also stimulates the p38 MAP kinase and the stress-activated protein kinase/JNK MAP kinase although the pathways are less well characterized (20, 21).

Lipids have been well documented to inhibit glucose disposal and reduce insulin sensitivity although the underlying mechanisms are obscure. One possibility is through the Randle glucose-fatty acid cycle, in which lipid oxidation limits glucose metabolism by inhibition of pyruvate dehydrogenase (22). However, this is unlikely to be the full explanation for insulin resistance induced by lipids, and they may also reduce insulin sensitivity through inhibition at the level of signaling components. One possibility, supported by data from animal models of insulin resistance, is inappropriate activation of lipid-dependent PKC isoenzymes (23, 24). It is possible that this leads to interference with insulin action by phosphorylation and inhibition of one or more signaling intermediates. Alternatively, or in addition, lipids may cause attenuation of the insulin signal by mechanisms independent of PKC. For example, recent studies have shown that PKB activation can be reduced in the presence of ceramide (25-27), a lipid second messenger produced by sphingomyelinase activation, which can be also derived from free fatty acids by de novo synthesis (28). The possibility therefore exists that different lipids may affect insulin action in different ways because of the specific signaling pathways which they affect.

To study the effects of lipids on insulin signal transduction, we have developed a model using mouse skeletal muscle C2C12 myotubes. Preincubation of the cells with unsaturated and saturated FFAs led to distinct effects on the insulin sensitivity of glycogen synthesis, and also on the state of activation of several signaling components. Our observations with the saturated FFA palmitate led us to hypothesize that this lipid was acting through elevation of intracellular ceramide and inhibition at the level of PKB. Further investigation confirmed that ceramide levels were indeed elevated in the myotubes and that addition of exogenous ceramide produced palmitate-like effects both on glycogen synthesis and signaling molecules. In addition to providing insights into the mechanism for palmitate-induced insulin resistance, these results demonstrate that this model will be useful in studying the attenuation of insulin signaling by other lipids or further factors causing insulin resistance.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- EMEM was from Trace Biosciences (Sydney, NSW, Australia). Bovine FCS was from Life Technologies, Inc. (Gaithersburg, MD). Gelatin was from Difco Laboratories (Detroit, MI). Fatty acid free bovine serum albumin was from ICN Biomedicals Inc. (Aurora, OH). Protein A-Sepharose, oleic acid, linoleic acid, and palmitic acid were from Sigma Chemical Co. Insulin was from Novo Nordisc (Copenhagen, Denmark). AG 1-X8 resin was from Bio-Rad Laboratories Pty. Ltd. (Sydney, NSW, Australia). RC20H anti-phosphotyrosine antibodies conjugated to horseradish peroxide were from Transduction Laboratories (Lexington, KY). IRS-1 antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Silica gel 60 F254 TLC plates were from Merck (Kilsyth, Vic, Australia). SB203580 and antibodies to PI3-kinase p85 subunit, GSK-3alpha , and phospho-Ser-21-GSK-3alpha were from Upstate Biotechnology (Lake Placid, NY). Antibodies to p44/42 MAP kinase and phospho-Thr-202/Tyr-204-p44/42 MAP kinase; p38 MAP kinase and phospho-Thr-180/Tyr-182-p38 MAP kinase; JNK MAP kinase and phospho-Thr-183/Tyr-185-JNK MAP kinase; PKB, phospho-Thr-308-PKB and phospho-Ser-473-PKB were from New England Biolabs (Beverly, MA). Glycogen synthase antibodies were a kind gift from Dr. John Lawrence, University of Virginia. PD98059 was from Biomol Research Laboratories Inc. (Plymouth Meeting, PA). Other reagents were from Sigma Chemical Co. or BDH (Merck).

Cell Culture-- C2C12 myoblasts were maintained in EMEM supplemented with 10% (v/v) FCS, 2 mM glutamate, 15 mM Hepes, pH 7.5, 500 IU/ml penicillin, and 100 µg/ml streptomycin (here termed 10% FCS-EMEM), in 95% O2, 5% CO2. To obtain fully differentiated myotubes, cells were grown to 90% confluency and incubated for 1 day in the above medium containing only 1% (v/v) FCS (here termed 1% FCS-EMEM). Cells were then seeded at a density of 7 × 104 cell/cm2 into 10-cm dishes or 6-well plates precoated with 1% (w/v) gelatin, in 1% FCS-EMEM containing 10 µM cytosine-1beta -D-arabinofuranoside. Medium was replaced at 1 and 2 days, and after 4 days myotubes were returned to 1% FCS-EMEM alone and used for experiments after a further 24 h.

Lipid Preincubations-- Lipid-containing media were prepared by conjugation of FFAs with BSA, by a method modified from that described by Svedberg et al. (29). Briefly, FFAs were dissolved in ethanol and diluted 1:25, in either 1% FCS-EMEM or EMEM containing no FCS (here termed SF-EMEM) at 45 °C, each containing 20% (w/v) fatty acid-free bovine serum albumin. Solutions were filter-sterilized and diluted 1:4 with 1% FCS- or SF-EMEM as appropriate. Control media prepared similarly contained ethanol and BSA in the absence of lipid. The pH of all media was still approximately 7.5. Myotubes were incubated for 16 h in 10 ml/dish or 2 ml/well 1% FCS-EMEM followed by a 2-h period in 5 ml/dish or 1 ml/well SF-EMEM in the absence or presence of FFAs.

Glycogen Assays-- Lipid-pretreated myotubes in 6-well plates were incubated for 1 h in 1 ml/well SF-EMEM containing D-[U-14C]glucose (4 µCi/ml) in the absence or presence of 100 nM insulin and FFAs as stated in the figure legends, and glycogen production was assayed by a method adapted from that described by Berti et al. (30). Cells were washed four times with 2 ml of ice-cold PBS and scraped into 300 µl/well 1 M KOH. Extracts were heated to 100 °C for 10 min, and 5 µl aliquots were taken for measurement of protein concentration by the method of Bradford (31). After addition of 40 µl of a saturated solution of Na2SO4, glycogen was precipitated by the addition of 700 µl ice-cold acetone and incubation at -70 °C for 30 min. Samples were centrifuged at 20,000 g and supernatants aspirated. Pellets were washed by resuspension in 50 µl of water followed by addition of 500 µl of ice-cold acetone and recentrifugation. Final pellets were dissolved in 100 µl of water, mixed with 1 ml of scintillant and counted for radioactivity.

Glucose Uptake/Phosphorylation Assays-- Lipid-pretreated myotubes were incubated, washed, and extracted as described for glycogen assays, except that D-[U-14C]2-deoxyglucose (1 µCi/ml) was used. After aliquots were taken for measurement of protein concentration, glucose uptake, and phosphorylation was determined by a method adapted from that described by Ferré et al. (32). Universal Indicator was added to extracts which were then neutralized by the addition of 25% perchloric acid and centrifuged at 13,000 rpm for 1 min. Supernatants were applied to 0.5 ml of AG 1-X8 columns previously equilibrated with water, for separation of free 2-deoxyglucose from phosphorylated 2-deoxyglucose. Free 2-deoxyglucose was eluted with 5 ml of water and then phosphorylated 2-deoxyglucose with 3 ml of 1 M HCl. Eluates were counted for radioactivity after addition of 25 ml of scintillant. Measurements of free and phosphorylated 2-deoxyglucose indicated that over 90% of total 2-deoxyglucose was recovered as the phosphorylated form.

IRS-1 Immunoprecipitation and PI3-Kinase Assays-- Lipid-pretreated myotubes in 10-cm dishes were incubated for 10 min in 5 ml of SF-EMEM in the absence or presence of 100 nM insulin and FFAs, and IRS-1-associated PI3-kinase activity assayed in a method adapted from those described by Folli et al. (33), Goodyear et al. (4), and Bjornholm et al. (34). Cells were washed twice with 5 ml of ice-cold PBS and scraped into 500 µl of extraction buffer (50 mM Hepes, pH 7.5, 150 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 2 mM Na3VO4, 10 mM Na4P2O7, 10 mM NaF, 2 mM EDTA, 1% (v/v) Nonidet P40, 10% (v/v) glycerol, 2 µg/ml aprotinin, 5 µg/ml leupeptin, 0.2 mM phenylmethylsulfonyl fluoride and 2 mM benzamidine). After sonication (15 pulses using a Branson 250 Sonifier and microtip at 20% duty cycle, power setting 2) lysates were centrifuged at 20,000 g for 10 min at 4 °C. Pellets were discarded and 2 µl of IRS-1 antibody was added to supernatants, which were then rocked gently overnight at 4 °C. After addition of 50 µl of a 1:1 suspension of protein A-Sepharose in 20 mM Hepes, pH 7.5, 180 mM NaCl, and further rocking for 1.5 h, lysates were briefly centrifuged at 3000 × g. The supernatants were retained for analysis of signaling intermediates by immunoblotting, while the immunoprecipitates were washed by centrifugation: twice with 100 µl of PBS, 1% (v/v) Nonidet P40, and 100 µM Na3VO4, twice with 100 µl of 100 mM Tris-HCl, pH 7.5, 500 mM LiCl, and 100 µM Na3VO4 and once with 100 µl of 10 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA, and 100 µM Na3VO4. For PI3-kinase assays, immunoprecipitates were resuspended in 200 µl of 20 mM Hepes, pH 7.5, 180 mM NaCl, and split into equal aliquots for assay in triplicate. Aliquots were prewarmed for 5 min at 30 °C, followed by addition of 25 µl of assay buffer (28 mM Hepes, pH 7.5, 50 mM NaCl, 0.15% (v/v) Nonidet P40, 12.5 mM MgCl2, 0.4 mM EGTA, 0.8 mg/ml L-alpha -phosphatidylinositol, 50 µM [gamma -32P]ATP (10 µCi/assay)). Reactions were terminated after 15 min by addition of 50 µl of 2 M HCl followed by 160 µl CHCl3. Assays were vortexed, briefly centrifuged at 3000 × g and 75 µl of the lower phase transferred to chilled tubes containing 80 µl of CH3OH, 1 M HCl (1:1 v/v). The tubes were vortexed, briefly centrifuged at 3000 × g and 30 µl of the lower phase applied to TLC plates. Plates were developed in CHCl3:CH3OH:NH4OH:H20 (60:47:11:5 by volume). L-alpha -phosphatidylinositol-4-phosphate (10 µg) was used as a standard and visualized with iodine vapor. Relative radioactivity of lipids co-migrating with the standard was determined by phosphorimaging using a Medical Dynamics 445 Phosphorimager and densitometry using IP Lab Gel software (Signal Analytics, Vienna, VA). Alternatively, washed immunoprecipitates were subjected to SDS-PAGE after addition of 50 µl of Laemmli sample buffer (35) and immunoblotting to assess IRS-1 tyrosine phosphorylation and p85 subunit association.

Immunoblotting-- After dilution of 300 µl of the supernatants remaining after IRS-1 immunoprecipitation with 100 µl of Laemmli sample buffer and heating at 100 °C for 2 min, 20-µl samples were subjected to SDS-PAGE, immunoblotting, and densitometry as described previously (23). Alternatively, cells in 6-well plates were washed twice with ice-cold PBS after treatments as stated in figure legends, and scraped into 500 µl of Laemmli sample buffer. After sonication and heating at 100 °C for 2 min, immunoblotting was carried out as above. All antibodies used were diluted 1:1000 except p85 antibodies (1:3000) and RC20H anti-phosphotyrosine antibodies (1:2500). When membranes had been probed with phospho-specific antibodies for GSK-3alpha , PKB, or MAP kinases, they were stripped by incubation in 62.5 mM Tris-HCl, pH 6.7, 2% (w/v) SDS, and 100 mM 2-mercaptoethanol for 30 min at 50 °C, extensively washed, and reprobed with the relevant antibodies for total kinase protein so that densitometric analyses could be corrected for loading variations.

Ceramide Assays-- Myotubes in 10-cm dishes were preincubated in the absence or presence of FFAs as described for IRS-1 immunoprecipitation. Media was aspirated after the 2-h serum-free period, and cells scraped into 0.7-ml ice-cold 1 M NaCl. This extract was quickly added to 3 ml of CHCl3:CH3OH (1:2, v/v) and vortex mixed. After addition of 1 ml of 1 M NaCl and 1 ml of CHCl3 and further mixing, phases were separated by centrifugation at 5000 × g for 2 min. Lipid extracts in the lower CHCl3 phase were stored at -20 °C under nitrogen and assayed within 4 days. Ceramide content was determined using a radiometric diacylglycerol assay kit (Amersham Pharmacia Biotech) according to the manufacturer's instructions, as diacylglycerol kinase can phosphorylate both diacylglycerols and ceramides (36). To improve separation of phosphatidic acid and ceramide-1-phosphate by TLC, plates were first developed with CHCl3:CH3OH:NH4OH (65:35:7.5, v/v/v), dried, and then developed with CHCl3:CH3OH:CH3COOH:(CH3)2CO:H20 (10:2:3:4:1, by volume) (37). 32P-labeled phosphatidic acid and ceramide-1-phosphate were identified after phosphorimaging by co-migration with authentic standards.

Statistical Methods-- All results are expressed as means ± S.E. Statistical calculations using Student's t test were performed using Statview S.E. + Graphics for Macintosh (Abacus Concepts, Berkeley, CA).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Effects of FFA Preincubation on Insulin-stimulated Glycogen Synthesis and Glucose Uptake in C2C12 Myotubes-- C2C12 myotubes exhibited a 2-fold stimulation of glycogen synthesis in the presence of 100 nM insulin during a 1-h incubation period, from 11 to 22 nmol of glucose units/h·mg of protein (Fig. 1A). This was used as a marker for insulin sensitivity so that the effects of lipids on insulin-signaling steps could be assessed. Three FFAs were used in experiments to induce insulin resistance in this system: the mono-unsaturated FFA oleate (18:1n-9), the di-unsaturated FFA linoleate (18:2n-6), and the saturated FFA palmitate (16:0), which are among the most common fatty acids found in muscle (38). Preliminary experiments (not shown) using lipid concentrations from 0.5 to 2 mM (within the physiological serum range) established that an approximately 50% decrease in total glycogen synthesis in the presence of insulin was obtained using 2 mM oleate, 1 mM linoleate, or 0.75 mM palmitate (Fig. 1A). Interestingly, the unsaturated FFAs also had a significant effect on basal glycogen synthesis, whereas palmitate was without effect, suggesting that the mechanisms involved might be distinct. None of the lipids affected the levels of glycogen synthase protein expressed in the myotubes, as determined by immunoblotting (data not shown).


View larger version (26K):
[in this window]
[in a new window]
  		Fig. 1.   Effect of FFA preincubation of C2C12 myotubes on insulin-stimulated glycogen synthesis and glucose uptake and phosphorylation. Myotubes in 6-well plates were incubated overnight with 1% FCS-EMEM followed by 2 h with SF-EMEM, all in the absence or presence of 2 mM oleate, 1 mM linoleate, or 0.75 mM palmitate as detailed under "Experimental Procedures." Myotubes were then incubated without or with 100 nM insulin in fresh SF-EMEM, in the presence of [14C]glucose (A) or [14C]-2-deoxyglucose (B) for 1 h, again in the absence or presence of the FFAs, and extracted with 1 M KOH for determination of glycogen synthesis or glucose uptake and phosphorylation. Results shown are combined means from six (A) or two (B) independent experiments, each carried out in triplicate. ***, p < 0.005; **, p < 0.02 lipid-treated versus appropriate basal or insulin-stimulated control.

Because it was possible that the lipid treatments affected glucose uptake and so restricted glucose availability for glycogen synthesis, we also determined glucose uptake and phosphorylation by the cells under identical conditions, using radiolabeled 2-deoxyglucose (Fig. 1B). C2C12 myotubes exhibited little if any stimulation of glucose uptake and phosphorylation in the presence of 100 nM insulin (approximately 250 nmol/h·mg protein in control cells), in agreement with the increase from 1.9 to 2.2 nmol/min·mg protein observed by others (39). Moreover, in contrast to their differing effects on glycogen synthesis, all three lipids gave essentially similar effects on glucose uptake, reducing the uptake and phosphorylation of 2-deoxyglucose by less than 20%. The 10-fold excess of phosphorylated glucose available for glycogen synthesis and the relatively minor reductions observed in the presence of FFAs, taken together with the absence of an effect of palmitate on basal glycogen synthesis, suggest that the observed lipid-specific alterations in glycogen synthesis are unlikely to result from decreased glucose availability.

Investigation of the Effects of FFA Preincubation on the PKB Signaling Pathway-- To determine where, in the pathways upstream of glycogen synthase, FFAs were exerting their effects, we first investigated the level of Ser-21 phosphorylation of GSK-3alpha and Ser-473 phosphorylation of PKB in lysates of myotubes, prepared after FFA treatment and insulin stimulation, using phospho-specific antibodies. A representative experiment is shown in Fig. 2A together with the means of densitometric analysis of five independent experiments in Fig. 2B. While palmitate pretreatment of myotubes resulted in inhibition of the insulin-stimulated phosphorylation of both GSK-3 and PKB, in agreement with its effect on glycogen synthesis, neither oleate nor linoleate pretreatment affected the phosphorylation state of these kinases (Fig. 2). Similar results were obtained using a phospho-specific antibody directed against the Thr-308 phosphorylation site of PKB (not shown). No effects of FFA pretreatment were seen on basal levels of phosphorylation of either kinase, nor did any treatment affect the total levels of PKB or GSK-3alpha expression (not shown). These results indicate that while the saturated FFA palmitate may inhibit insulin-stimulated glycogen synthesis through effects on the PKB signaling pathway, the unsaturated FFAs do not inhibit insulin action at this site.


View larger version (26K):
[in this window]
[in a new window]
  		Fig. 2.   Effect of FFA preincubation of C2C12 myotubes on insulin-stimulated phosphorylation of GSK-3 and PKB. A, myotubes in 10-cm dishes were pretreated with FFAs as given for Fig. 1. Myotubes were then incubated without or with 100 nM insulin in fresh medium for 10 min, again in the absence or presence of the FFAs, and lysates were prepared as detailed under "Experimental Procedures" for SDS-PAGE and immunoblotting with phospho-specific antibodies to GSK-3 or PKB. B, the means from densitometry of 5 independent experiments are shown. For these and all other immunoblots shown in subsequent figures, data of phosphorylated kinases were corrected using measurements of total kinase immunoreactivity, obtained from the same membranes by stripping of antibodies and reprobing as detailed under "Experimental Procedures." **, p < 0.02; ***, p < 0.005 palmitate-treated versus control insulin-stimulated phosphorylation.

FFA Effects on IRS-1 Tyrosine Phosphorylation, p85 Association, and PI3-Kinase Activation-- Because palmitate pretreatment was found to affect signaling through the PKB pathway, we next determined whether this lipid affected insulin action at the level of IRS-1, including the association and activation of PI3-kinase, because these components lie upstream of PKB activation. IRS-1 was immunoprecipitated from cell lysates, prepared from myotubes that had been pretreated with FFAs, and incubated in the absence or presence of insulin, and the immunoprecipitates were assayed for PI3-kinase activity (Fig. 3). No significant difference in insulin-stimulated PI3-kinase activity was observed between control and palmitate-treated myotubes, while oleate and linoleate pretreatment had minor though statistically significant inhibitory effects (Fig. 3). Basal PI3-kinase activities were similar after all treatments. Immunoprecipitates from palmitate-treated cells were also subjected to SDS-PAGE and immunoblotting, to determine the extent of tyrosine phosphorylation and association of the p85 subunit of PI3-kinase stimulated by insulin (Fig. 4). In agreement with the absence of a palmitate effect on PI3-kinase activity, no significant difference was observed between control and palmitate-treated myotubes in the insulin-stimulated tyrosine phosphorylation of IRS-1 or co-immunoprecipitation with p85.


View larger version (52K):
[in this window]
[in a new window]
  		Fig. 3.   Effect of FFA preincubation of C2C12 myotubes on insulin-stimulated PI3-kinase activity in IRS-1 immunoprecipitates. A, IRS-1 was immunoprecipitated from C2C12 lysates, prepared from myotubes treated as in Fig. 2, and immunoprecipitates were assayed for PI3-kinase activity as detailed under "Experimental Procedures." Lipid extracts from assays were subjected to TLC and phosphorimaging. B, the means from densitometry of 5 independent experiments each carried out in triplicate are shown. **, p < 0.01 oleate- and linoleate-treated versus control insulin-stimulated PI3-kinase activity.


View larger version (23K):
[in this window]
[in a new window]
  		Fig. 4.   Effect of palmitate preincubation of C2C12 myotubes on insulin-stimulated IRS-1 tyrosine phosphorylation and p85 co-immunoprecipitation. A, IRS-1 immunoprecipitates prepared as in Fig. 3 were subjected to SDS-PAGE and immunoblotting using either phosphotyrosine (IB: Tyr-P) or p85 (IB: p85) antibodies as indicated. B, the means from densitometry of three independent experiments are shown. *, p < 0.05 palmitate-treated versus control basal IRS-1 tyrosine phosphorylation.

FFA Effects on MAP Kinase Phosphorylation-- The palmitate-induced inhibition of insulin signaling from IRS-1 to glycogen synthase appears to originate downstream of PI3-kinase activation but upstream of PKB phosphorylation. While a reduction in the GSK-3-mediated phosphorylation of glycogen synthase appears to be the major mechanism of regulation of glycogen synthesis, there is also some evidence that insulin-stimulated dephosphorylation of the enzyme is mediated through the ERK MAP kinase pathway. We therefore investigated the effects of FFA pretreatment on the insulin sensitivity of ERK1/2 MAP kinase phosphorylation in myotubes to assess whether this pathway is also affected. C2C12 cells were found to express mainly the p42 (ERK1) form of ERK MAP kinase, which exhibited a 4-fold increase in dual Thr-202/Tyr-204 phosphorylation in response to insulin, indicating activation (Fig. 5A). While the unsaturated FFAs oleate and linoleate had little effect on p42 ERK phosphorylation, palmitate pretreatment resulted in a 3-fold increase in basal phosphorylation and a 2.8-fold increase in the insulin-stimulated dual phosphorylation of this kinase, indicating both chronic activation and a potentiation of effects between insulin and the saturated FFA (Fig. 5B).


View larger version (22K):
[in this window]
[in a new window]
  		Fig. 5.   Effect of FFA preincubation of C2C12 myotubes on insulin-stimulated phosphorylation of MAP kinases. A, myotubes in 10-cm dishes were pretreated with FFAs, challenged with 100 nM insulin for 10 min, and lysates were prepared as given for Fig. 2. Samples were immunoblotted with phospho-specific antibodies to ERK1/2 MAP kinase and p38 MAP kinase. Representative blots are shown. B, the means from densitometry of five independent experiments are shown. **, p < 0.02; ***, p < 0.005 for palmitate-treated versus control MAP kinase phosphorylation.

While the stimulation of the ERK MAP kinase pathway by insulin, through activation of Ras, has been well characterized, the effects of the hormone on JNK and p38 MAP kinases have been less studied. Because these kinases lie on parallel signaling pathways which may exhibit cross-talk at the level of upstream components, we investigated whether the enhanced ERK MAP kinase phosphorylation by palmitate pretreatment was accompanied by activation of JNK or p38 MAP kinases. Insufficient levels of JNK MAP kinases were detected in immunoblots using phospho-JNK MAP kinase antibodies to permit densitometry, and these enzymes were not further investigated. In contrast, p38 MAP kinase was readily detected: insulin did not increase phosphorylation of this kinase, nor did oleate and linoleate. However, lysates from palmitate-treated myotubes exhibited 7-10-fold increased phosphorylation of p38 MAP kinase (Fig. 5). These results suggest that the oleate and linoleate effects on glycogen metabolism are not mediated through the MAP kinase pathways although the possibility remains that they reduce the phosphatase activity regulating glycogen synthase.

Investigation of the Role of Ceramide and MAP Kinases in Palmitate-induced Insulin Resistance-- Recently, activation of the Ras-MAP kinase pathway has been demonstrated downstream of a ceramide-induced activation of KSR/CAPK, and was found to inhibit PKB in the absence of an effect on PI3-kinase (25). Because the data presented here for palmitate-pretreated cells is in agreement with such a mechanism, we investigated whether palmitate could be acting through the elevation of ceramide levels in the myotubes. Ceramide was measured in cells preincubated in the absence or presence of FFAs and was found to be elevated 2.1-fold by palmitate (Fig. 6). In contrast, oleate and linoleate were without effect. Furthermore, preincubation of myotubes with increasing concentrations of C2-ceramide gave similar results to those obtained by palmitate pretreatment: both insulin-stimulated glycogen synthesis (Fig. 7A) and PKB phosphorylation (Fig. 7B) were inhibited, while ERK MAP kinase phosphorylation was enhanced at C2-ceramide concentrations above 10 µM (Fig. 7B).


View larger version (34K):
[in this window]
[in a new window]
  		Fig. 6.   Measurement of ceramide levels in FFA-pretreated myotubes. A, myotubes in 10-cm dishes were pretreated without or with FFAs as given in Fig. 2. Lipid extracts were prepared and assayed for ceramides as detailed under "Experimental Procedures." A phosphorimage of phosphorylated ceramides from samples and standards, separated by TLC is shown. B, the means from densitometry of two independent experiments carried out in duplicate are shown. ***, p < 0.001 for palmitate-treated versus control.


View larger version (22K):
[in this window]
[in a new window]
  		Fig. 7.   Effect of C2-ceramide preincubation on glycogen synthesis, PKB, and ERK MAP kinase phosphorylation in C2C12 cells. A, myotubes were preincubated for 2 h in SF-EMEM with increasing concentrations of C2-ceramide or vehicle (0.1% v/v Me2SO), in the absence of BSA. Myotubes were then incubated without or with 100 nM insulin in fresh medium in the presence of [14C]glucose for 1 h, again in the absence or presence of increasing concentrations of C2-ceramide and extracted for determination of glycogen synthesis. The means from two experiments carried out in triplicate are shown. **, p < 0.02; ***, p < 0.001 versus untreated controls. B, myotubes preincubated as in panel A were also incubated without or with 100 nM insulin in fresh medium for 10 min, again in the absence or presence of increasing concentrations of C2-ceramide, and lysates were prepared as detailed under "Experimental Procedures." Samples were immunoblotted with phospho-specific antibodies to PKB or ERK MAP kinase as indicated. C, results from densitometry of two experiments are shown. ***, p < 0.005 versus untreated controls.

The results presented in Figs. 5 and 7 had suggested that the palmitate-induced inhibition of insulin-stimulated PKB, and hence of glycogen synthesis, may be mediated through overactivation of ERK or p38 MAP kinases by ceramide. There is some precedence for this, at least in the case of ERK MAP kinase, from other experimental systems (26, 27). We therefore examined the effects of the MAP kinase kinase inhibitor PD98059, which reduces ERK MAP kinase activation, on both palmitate- and ceramide-induced insulin resistance in C2C12 myotubes. Cells were preincubated in the absence and presence of palmitate or ceramide as before, in combination with PD98059 treatment, prior to insulin stimulation, and the effects on glycogen synthesis and kinase phosphorylation state were determined. While the inhibitor was confirmed to be effective in the inhibition of ERK1 phosphorylation, there was no improvement in the reduced insulin sensitivity of phosphorylation of PKB after either palmitate or ceramide pretreatment (Fig. 8). Similarly, the inhibition of insulin-stimulated glycogen synthesis was not affected (not shown). Using the p38 MAP kinase-specific inhibitor SB203580, we were also able to assess the contribution of p38 to the insulin resistance caused by palmitate or ceramide. Again, there was no improvement in either the reduced insulin sensitivity of glycogen synthesis, or in the reduced phosphorylation of PKB, in the presence of 50 µM SB203580 (not shown).These results suggest that while palmitate pretreatment may inhibit the PKB pathway through increased production of ceramide, this effect is not mediated through increased activation of the ERK and p38 MAP kinase pathways. However, the close agreement between the results obtained with palmitate (Fig. 8, A and B) and those obtained with ceramide (Fig. 8, C and D) again strongly suggest that the effects of palmitate are mediated by ceramide.


View larger version (37K):
[in this window]
[in a new window]
  		Fig. 8.   Effect of PD98059 on palmitate- and ceramide-induced alterations in insulin-stimulated PKB and ERK phosphorylation. A, myotubes in 6-well plates were pretreated with the combinations of palmitate and 50 µM PD98059 indicated, as given for Fig. 2. Cells were incubated without or with 100 nM insulin in fresh medium for 10 min, also in the absence or presence of palmitate and PD98059, and lysates were prepared and samples immunoblotted with phospho-specific antibodies to PKB and ERK1/2 MAP kinase. B, the results from densitometry of two experiments are shown. *, p < 0.05; ***, p < 0.005, palmitate versus control; **, p < 0.01, palmitate + PD98059 versus palmitate untreated. C and D, myotubes were treated with the combinations of C2-ceramide and PD98059 indicated, as given for Fig. 7. Other details are as for panels A and B. ***, p < 0.005, ceramide versus control; dagger , p < 0.005, ceramide + PD98059 versus ceramide untreated.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The work described here is an extensive study of the mechanisms of lipid-induced insulin resistance of glycogen synthesis in C2C12 skeletal muscle cells, addressing the effects of FFAs on the signaling pathway from IRS-1 to glycogen synthase, as well as on MAP kinases. While we have shown that overnight preincubation with either saturated or unsaturated FFAs can inhibit glycogen synthesis, our results indicate that these lipids probably act via different mechanisms. Palmitate preincubation affected only the insulin-stimulated component of glycogen synthesis, but did not affect immediate signaling from the insulin receptor, in that IRS-1 tyrosine phosphorylation and PI3-kinase recruitment appeared unimpaired. However, it did reduce activation of the downstream PKB pathway, which is a major regulatory input for glycogen synthase. In contrast, palmitate potentiated insulin-stimulated activation of the concurrent ERK MAP kinase pathway. This FFA also activated p38, another MAP kinase family member. Conversely, the unsaturated FFAs oleate and linoleate had no effect on the PKB or MAP kinase pathways although inhibition of both basal and insulin-stimulated glycogen synthesis was observed, and insulin-stimulated PI3-kinase activity was also slightly reduced.

These results, and the observation that the presence of the beta -oxidation inhibitor etomoxir was unable to protect against the effects of oleate on glycogen synthesis,2 indicate that inhibition of glucose metabolism by FFAs is not explained purely by Randle glucose-fatty acid cycle effects but that different lipids can exert specific effects at the level of the insulin-signaling cascade. However, it is possible that the observed FFA-induced alterations in glucose uptake and phosphorylation occur as a consequence of basic competition between accumulated lipid and glucose (22). The absence of an effect of insulin on glucose uptake in our system may be because of the fact that C2C12 cells express predominantly the GLUT1 glucose transporter (30) rather than the insulin-sensitive GLUT4 isoform.

The data presented here clearly suggest that palmitate acts downstream of IRS-1 and PI3-kinase. While it might be argued that palmitate affected signaling from the insulin receptor via another adaptor protein such as IRS-2, which might influence the PKB pathway to a greater extent, IRS-1 appears to be the major IRS in skeletal muscle (12). Furthermore, IRS-2 tyrosine phosphorylation in response to insulin appears to be more transient (40), and we have detected relatively little insulin-stimulated tyrosine phosphorylation in IRS-2 immunoprecipitates from C2C12 cells,2 making such an explanation unlikely. Finally, we have also observed inhibition of PKB phosphorylation in response to EGF in palmitate-pretreated cells.2 Because PI3-kinase activation by EGF occurs by direct interaction with the EGF receptor rather than through IRS-1, this again suggests that palmitate acts downstream of IRS docking proteins to inhibit stimulation of PKB.

Activation of the Ras-MAP kinase pathway by CAPK, also known as KSR, has been demonstrated concomitantly with the inhibition of the PKB pathway, independently of PI3-kinase, in COS-7 cells treated with ceramide (25). Furthermore, palmitate is a precursor of ceramide (28), and ceramide treatment of 3T3-L1 adipocytes and COS-7 cells gave rise to similar inhibition of PKB but not PI3-kinase to that seen here with palmitate (26, 27). Taken together with our findings that palmitate elevates the levels of ceramides in C2C12 myotubes and that exogenously added C2-ceramide also caused inhibition of PKB phosphorylation but stimulation of MAP kinase phosphorylation, these observations strongly suggest that ceramide synthesis is sufficient to explain the inhibition of insulin-stimulated glycogen synthesis by palmitate.3

The increase in ceramides in the myotubes caused by the FFA was approximately 2-fold and similar to that previously reported during the development of skeletal muscle insulin resistance in whole animals (36). Other studies have suggested a role for ceramide in the inhibition of insulin signaling, also downstream of PI3-kinase, including in the induction of insulin resistance by TNFalpha in 3T3-L1 adipocytes (41). Because, in our system with C2C12 myotubes, inhibition of ERK MAP kinase with PD98059 or of p38 MAP kinase with SB203580 did not protect against palmitate- or ceramide-induced insulin resistance, and since ceramide does not lead to ERK MAP kinase phosphorylation in 3T3-L1 adipocytes while still inhibiting PKB (27), it is likely that ceramide can also lead to reduced PKB phosphorylation independently of these MAP kinases. Studies of ceramide effects indicate that coupling of this lipid to specific signaling cascades is both stimulus and cell-type specific (reviewed in Ref. 42).

While we have established that palmitate acts at the level of PKB, reducing phosphorylation at both Thr-308 and Ser-473, it remains to be determined whether this effect involves inhibition of PDK activity and/or enhanced dephosphorylation. A recent study has shown that PKB inhibition by hyperosmotic stress involves both inhibition of phosphorylation of these regulatory sites and also rapid dephosphorylation by PP2A, while PI3-kinase activity is unaffected (43). Interestingly, in addition to activation of KSR/CAPK, ceramide may also act through CAPP (44), a member of the PP2A family which undergoes inhibition upon insulin stimulation and which may act antagonistically to the hormone (17). It is therefore possible that palmitate promotes PKB dephosphorylation by activation of CAPP. An additional ceramide-dependent inhibition of insulin-stimulated glycogen synthesis may involve the inactivation of PP1 by KSR/CAPK, leading to reduced dephosphorylation and activation of glycogen synthase (17).

While the effects of the unsaturated FFAs, oleate and linoleate, on insulin signaling through PI3-kinase and PKB to glycogen synthase were also characterized in the present study, the results did not provide significant insights into the mechanisms by which these lipids reduce glycogen synthesis both in the absence and presence of insulin. These FFAs neither elevated ceramide levels nor affected MAP kinases in the myotubes. The fact that slight inhibition of PI3-kinase because of these lipids was not accompanied by a corresponding inhibition of PKB and GSK-3 phosphorylation was unexpected and suggests that only threshold PI3-kinase activation may be necessary to activate the PKB pathway. Alternative possibilities to explain the inhibitory effects of oleate and linoleate include attenuated dephosphorylation of glycogen synthase or alterations in PKC activity (23).

Our results extend previous observations of lipid effects on insulin sensitivity in other models. Several studies, involving the preincubation of adipocytes (45, 46) or muscle cell lines (9, 47) with different lipid species, have demonstrated inhibition of insulin-stimulated glucose utilization, although effects on signaling intermediates were not addressed. In hepatocytes, the inhibitory effects of several species of FFAs, including oleate and palmitate, on insulin-stimulated aminoisobutyric acid transport were partly explained by alterations in insulin receptor internalization and recycling (29). While we have not addressed this possibility directly, a nonselective effect of FFAs on upstream signaling is unlikely to make an important contribution to the inhibition of glycogen synthesis seen here, which was associated with palmitate-specific inhibition at the level of PKB. Consistent with our results, in rat-1 fibroblasts, overexpressing insulin receptors, 4-h preincubation with 1 mM palmitate again led to a decrease in the insulin sensitivity of glucose utilization, and no effect was observed on IRS-1 tyrosine phosphorylation or PI3-kinase activity (48). However, a decrease in insulin-stimulated MAP kinase activity was observed, as opposed to the potentiation between palmitate and insulin we have observed in myotubes. Such discrepancies may indicate cell-specific effects of lipids, and the use of well differentiated myotubes in the system we describe is clearly an advantage.

In summary, we have developed a model of lipid-induced skeletal muscle insulin resistance using mouse C2C12 myotubes. This has led to the identification of specific insulin-signaling steps which are affected by pretreatment with different FFAs. The unsaturated FFAs oleate and linoleate were without effect on PKB despite inhibition of PI3-kinase activation, and the mechanism by which they act remains to be determined. In contrast, the saturated FFA palmitate inhibits insulin activation of the PKB pathway downstream of IRS-1-associated PI3-kinase activation, and its effect is likely to be mediated by the de novo synthesis of ceramide.

    ACKNOWLEDGEMENTS

We thank Kim Bell and Drs. Greg Cooney and Alison Thompson for helpful discussions and François Karstens for experimental assistance.

    FOOTNOTES

* This work was supported by the National Health and Medical Research Council of Australia and in part by a research grant from Aza Research Pty. Ltd.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Tel.: 61-2-9295-8212; Fax: 61-2-9295-8201; E-mail: c.schmitz-peiffer@garvan.unsw. edu.au.

2 C. Schmitz-Peiffer, D. L. Craig, and T. J. Biden, unpublished observation.

3 In keeping with such a proposal, we have observed conversion of 3H-labeled palmitate into ceramide, as well as diacylglycerol and triglyceride, in C2C12 myotubes, upon TLC separation of lipid extracts. The amount of ceramide formed during palmitate treatment (approximately 600 pmol per 10-cm dish as determined from specific radioactivity) was in good agreement with the total levels determined by ceramide assay (approximately 1000 pmol per 10-cm dish determined by comparison with ceramide standards), and with levels reported in fibroblasts (37).

    ABBREVIATIONS

The abbreviations used are: PI3-kinase, phosphatidylinositol 3-kinase; BSA, bovine serum albumin; CAPP, ceramide-activated protein phosphatase; EMEM, minimum essential medium with Earles' salts; ERK, extracellular signal-regulated kinase; FCS, fetal calf serum; FFA, free fatty acid; GSK-3, glycogen synthase kinase-3; IRS, insulin receptor substrate; JNK, c-Jun N-terminal kinase; KSR, kinase suppressor of Ras; CAPK, ceramide-activated protein kinase; MAP kinase, mitogen-activated protein kinase; PBS, phosphate-buffered saline; PDK, PtdIns(3, 4, 5)P3-dependent kinase; PKB, protein kinase B; PKC, protein kinase C; PP1 and PP2A, protein phosphatase 1 and 2A, respectively; PtdIns(3,4,5)P3, phosphatidylinositol (3,4,5)-trisphosphate; TLC, thin layer chromatography; PAGE, polyacrylamide gel electrophoresis.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. DeFronzo, R. A., Gunnarsson, R., Bjorkman, O., Olsson, M., and Wahren, J. (1985) J. Clin. Invest. 76, 149-155
2. McGarry, J. D. (1992) Science 258, 766-770[Abstract/Free Full Text]
3. Borkman, M., Storlien, L. H., Pan, D. A., Jenkins, A. B., Chisholm, D. J., and Campbell, L. V. (1993) N. Engl. J. Med. 328, 238-244[Abstract/Free Full Text]
4. Goodyear, L. J., Giorgino, F., Sherman, L. A., Carey, J., Smith, R. J., and Dohm, G. L. (1995) J. Clin. Invest. 95, 2195-2204
5. Villarpalasi, C., and Farese, R. V. (1994) Diabetologia 37, 885-888[Medline] [Order article via Infotrieve]
6. Storlien, L. H., Kraegen, E. W., Chisholm, D. J., Ford, G. L., Bruce, D. G., and Pascoe, W. S. (1987) Science 237, 885-888[Abstract/Free Full Text]
7. Kraegen, E. W., Clark, P. W., Jenkins, A. B., Daley, E. A., Chisholm, D. J., and Storlien, L. H. (1991) Diabetes 40, 1397-1403[Abstract]
8. Eckel, J., and Reinauer, H. (1990) Biochem. Soc. Trans. 18, 1125-1127[Medline] [Order article via Infotrieve]
9. Shillabeer, G., Chamoun, C., Hatch, G., and Lau, D. C. W. (1995) Biochem. Biophys. Res. Commun. 207, 768-774[CrossRef][Medline] [Order article via Infotrieve]
10. Lawrence, J. C., and Roach, P. J. (1997) Diabetes 46, 541-547[Abstract]
11. White, M. F. (1998) Mol. Cell. Biochem. 182, 3-11[CrossRef][Medline] [Order article via Infotrieve]
12. Yamauchi, T., Tobe, K., Tamemoto, H., Ueki, K., Kaburagi, Y., Yamamotohonda, R., Takahashi, Y., Yoshizawa, F., Aizawa, S., Akanuma, Y., Sonenberg, N., Yazaki, Y., and Kadowaki, T. (1996) Mol. Cell. Biol. 16, 3074-3084[Abstract]
13. White, M. F. (1997) Diabetologia 40 Suppl. 2, 2-17[CrossRef]
14. Alessi, D. R., and Cohen, P. (1998) Curr. Opin. Gen. Dev. 8, 55-62[CrossRef][Medline] [Order article via Infotrieve]
15. Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. (1995) Nature 378, 785-789[CrossRef][Medline] [Order article via Infotrieve]
16. Skurat, A. V., and Roach, P. J. (1995) J. Biol. Chem. 270, 12491-12497[Abstract/Free Full Text]
17. Ragolia, L., and Begum, N. (1998) Mol. Cell. Biochem. 182, 49-58[CrossRef][Medline] [Order article via Infotrieve]
18. Holness, M. J., Fryer, L., and Sugden, M. C. (1997) Biochem. Soc. Trans. 25, 1-7[Medline] [Order article via Infotrieve]
19. Shulman, G. I., Rothman, D. L., Jue, T., Stein, P., DeFronzo, R. A., and Shulman, R. G. (1990) N. Engl. J. Med. 322, 223-228[Abstract]
20. Moxham, C. M., Tabrizchi, A., Davis, R. J., and Malbon, C. C. (1996) J. Biol. Chem. 271, 30765-30773[Abstract/Free Full Text]
21. Guo, J. H., Wang, H., and Malbon, C. C. (1998) J. Biol. Chem. 273, 16487-16493[Abstract/Free Full Text]
22. Randle, P. J., Kerbey, A. L., and Espinal, J. (1988) Diabetes Metab. Rev. 4, 623-638[Medline] [Order article via Infotrieve]
23. Schmitz-Peiffer, C., Browne, C. L., Oakes, N. D., Watkinson, A., Chisholm, D. J., Kraegen, E. W., and Biden, T. J. (1997) Diabetes 46, 169-178[Abstract]
24. Schmitz-Peiffer, C., Oakes, N. D., Browne, C. L., Kraegen, E. W., and Biden, T. J. (1997) Am. J. Physiol. 273, E915-E921[Abstract/Free Full Text]
25. Basu, S., Bayoumy, S., Zhang, Y., Lozano, J., and Kolesnick, R. (1998) J. Biol. Chem. 273, 30419-30426[Abstract/Free Full Text]
26. Zhou, H. L., Summers, S. K., Birnbaum, M. J., and Pittman, R. N. (1998) J. Biol. Chem. 273, 16568-16575[Abstract/Free Full Text]
27. Summers, S. A., Garza, L. A., Zhou, H. L., and Birnbaum, M. J. (1998) Mol. Cell. Biol. 18, 5457-5464[Abstract/Free Full Text]
28. Merrill, A., Jr., and Jones, D. D. (1990) Biochim. Biophys. Acta 1044, 1-12[Medline] [Order article via Infotrieve]
29. Svedberg, J., Bjorntorp, P., Smith, U., and Lonnroth, P. (1990) Diabetes 39, 570-574[Abstract]
30. Berti, L., Kellerer, M., Capp, E., and Haring, H. U. (1997) Diabetologia 40, 606-609[CrossRef][Medline] [Order article via Infotrieve]
31. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254[CrossRef][Medline] [Order article via Infotrieve]
32. Ferre, P., Leturque, A., Burnol, A. F., Penicaud, L., and Girard, J. (1985) Biochem. J. 228, 103-110[Medline] [Order article via Infotrieve]
33. Folli, F., Saad, M. J. A., Backer, J. M., and Kahn, C. R. (1992) J. Biol. Chem. 267, 22171-22177[Abstract/Free Full Text]
34. Bjornholm, M., Kawano, Y., Lehtihet, M., and Zierath, J. R. (1997) Diabetes 46, 524-527[Abstract]
35. Laemmli, U. K. (1970) Nature 227, 680-685[CrossRef][Medline] [Order article via Infotrieve]
36. Turinsky, J., O'Sullivan, D. M., and Bayly, B. P. (1990) J. Biol. Chem. 265, 16880-16885[Abstract/Free Full Text]
37. Martin, A., Duffy, P. A., Liossis, C., Gomezmunoz, A., Obrien, L., Stone, J. C., and Brindley, D. N. (1997) Oncogene 14, 1571-1580[CrossRef][Medline] [Order article via Infotrieve]
38. Gorski, J., Nawrocki, A., and Murthy, M. (1998) Mol. Cell. Biochem. 178, 113-118[CrossRef][Medline] [Order article via Infotrieve]
39. Moyers, J. S., Bilan, P. J., Reynet, C., and Kahn, C. R. (1996) J. Biol. Chem. 271, 23111-23116[Abstract/Free Full Text]
40. Ogihara, T., Shin, B. C., Anai, M., Katagiri, H., Inukai, K., Funaki, M., Fukushima, Y., Ishihara, H., Takata, K., Kikuchi, M., Yazaki, Y., Oka, Y., and Asano, T. (1997) J. Biol. Chem. 272, 12868-12873[Abstract/Free Full Text]
41. Wang, C. N., Obrien, L., and Brindley, D. N. (1998) Diabetes 47, 24-31[Abstract]
42. Kolesnick, R., and Kronke, M. (1998) Ann. Rev. Physiol. 60, 643-665[CrossRef][Medline] [Order article via Infotrieve]
43. Meier, R., Thelen, M., and Hemmings, B. A. (1998) EMBO J. 17, 7294-7303[CrossRef][Medline] [Order article via Infotrieve]
44. Hannun, Y. A. (1994) J. Biol. Chem. 269, 3125-3128[Free Full Text]
45. Hunnicutt, J. W., Hardy, R. W., Williford, J., and McDonald, J. M. (1994) Diabetes 43, 540-545[Abstract]
46. Van Epps-Fung, M., Williford, J., Wells, A., and Hardy, R. W. (1997) Endocrinology 138, 4338-4345[Abstract/Free Full Text]
47. Eckel, J., Asskamp, B., and Reinauer, H. (1991) Endocrinology 129, 345-352[Abstract]
48. Usui, I., Takata, Y., Imamura, T., Morioka, H., Sasaoka, T., Sawa, T., Ishihara, H., Ishiki, M., and Kobayashi, M. (1997) Diabetologia 40, 894-901[CrossRef][Medline] [Order article via Infotrieve]

Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J BiochemHome page
M. W. Ruddock, A. Stein, E. Landaker, J. Park, R. C. Cooksey, D. McClain, and M.-E. Patti
Saturated Fatty Acids Inhibit Hepatic Insulin Action by Modulating Insulin Receptor Expression and Post-receptor Signalling
J. Biochem., November 1, 2008; 144(5): 599 - 607.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
A.-L. Tardy, C. Giraudet, P. Rousset, J.-P. Rigaudiere, B. Laillet, S. Chalancon, J. Salles, O. Loreau, J.-M. Chardigny, and B. Morio
Effects of trans MUFA from dairy and industrial sources on muscle mitochondrial function and insulin sensitivity
J. Lipid Res., July 1, 2008; 49(7): 1445 - 1455.
[Abstract] [Full Text] [PDF]